Our observations that the effects of MET inhibition are influenced by EGFR-MET dimerisation and in turn EGFR genotype, suggest novel mechanisms to understand how best to target MET in NSCLC and highlight the importance of understanding the interaction between multiple driver mutations when facing treatment resistance. Here, MET is linked to non-small cell lung carcinoma.